Please refer the enclosed intimation regarding the in-principle approval of the Board of Directors of the Company for evaluation of the proposed restructuring of the radiology business ....

JBuSlyE 2L3im, 2i0te2d6 National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, DScarlaipl SCtoredeet:, 539871 BSyamndbroal K: TurHlaY RCoOmCAplReEx, Mumbai – 400001 Bandra (E), Mumbai – 400051 Sub: Disclosure und er Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/ Ma'am, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you as under: Nueclear Healthcare Limited ("Wholly Owned Subsidiary of the Company" / "NHL") is engaged in the business of advanced cancer diagnostics and nuclear medicine. NHL operates PET-CT and CT imaging centres, provides nuclear medicine diagnostic services and manufactures radiopharmaceuticals through its medical cyclotron facilities, supporting the early detection, diagnosis, staging and monitoring of cancer and other complex diseases. The Board of Directors of the Company, at its meeting held today, i.e., Thursday, July 23, 2026 discussed and in-principle approved the evaluation of a proposed demerger of NHL's radiology business undertaking to outside the group, by way of a scheme of arPrarnogpeomseedn tR oers tsrluumctpu rsianlge or business transfer or any other appropriate structure or mode, as may be evaluated, subject to requisite regulatory and statutory approvals (" "). The Proposed Restructuring is at an in-principle evaluation stage. The detailed terms of the proposed transaction shall be placed before the Board of Directors of NHL at the appropriate time, following which necessary disclosures and filings shall be made with the Stock Exchanges and other regulatory/statutory authorities, as applicable. The Company will ensure compliance with all applicable regulatory requirements, including under the Companies Act, 2013 and the Listing Regulations, at each stage of the Proposed Restructuring, including intimation to the Stock Exchanges. The above disclosures are also being made available on the website of the Company at https://investor.thyrocare.com. The Board Meeting commenced at 2:45 P.M. and concluded at 03:35 P.M. This is for your information and records. Thanking you, FYoour rTsh fayirtohcfualrley, Technologies Limited Brijesh Kumar Company Secretary & Compliance Officer